Core Insights - Merck (MRK.US) is actively pursuing acquisitions, product innovation, and new drug pipelines, which may significantly impact its future strategy and performance [1] Recent Events - Merck is in talks to acquire cancer drug developer Revolution Medicines for an estimated $28 billion to $32 billion, which would introduce the experimental drug Daraxonrasib targeting RAS gene mutation cancers, marking one of the largest deals in the pharmaceutical industry since Pfizer's acquisition of Seagen at the end of 2023 [2] - The company has also completed the acquisition of Cidara Therapeutics to strengthen its product pipeline [2] Business Progress - The subcutaneous formulation of Keytruda (Qlex) has been submitted for approval in the U.S., EU, and China, addressing challenges from the intravenous version's key patent expiration in 2028. Wolfe Research estimates that by 2029, approximately 41% of Keytruda's intravenous revenue may transition to the subcutaneous version [3] - New indications for Keytruda, including combination therapy with Moderna's mRNA vaccine and perioperative treatment for bladder cancer, are in progress [3] Performance Overview - The pulmonary arterial hypertension drug Winrevair (sotatercept) is projected to achieve sales of $1.443 billion by 2025 and is expected to receive FDA approval for new indications in 2026 [4] - The oral PCSK9 inhibitor Enlicitide has successfully completed Phase III clinical trials, potentially offering new options for cardiovascular disease patients [4] - The animal health business is expected to generate $6.4 billion in sales by 2025, reflecting an 8% year-over-year growth, while the diabetes drug sitagliptin is projected to generate $2.544 billion in revenue [4] Company Status - Merck's 2025 financial report anticipates 2026 sales between $65.5 billion and $67 billion, with adjusted EPS ranging from $5 to $5.15, which is below market expectations [5] - The company faces challenges including a decline in sales of the HPV vaccine Gardasil (projected at $5.2 billion for 2025, down 39% year-over-year), a slow recovery in the Chinese market, and a 12% decrease in R&D investment [5] Institutional Views - In January 2026, Wolfe Research upgraded Merck's rating to "Outperform" with a target price of $135, citing the company's position in a catalyst-rich phase through acquisitions and product innovation [6] - As of February 2, 2026, Merck's stock was priced at $113.37, reflecting a 14.72% increase over the past 52 weeks [6]

Group 1 - Eli Lilly (LLY.US) is in advanced talks to acquire Ventyx Biosciences (VTYX.US) for over $1 billion to expand its immunology business [1] - Ventyx's stock price surged by 62.59% to $16.34 in after-hours trading, indicating a market capitalization increase of $433.9 million based on the acquisition price [1] - The acquisition discussions coincide with the upcoming J.P. Morgan Healthcare Conference in San Francisco, a traditional hotspot for M&A activity in the pharmaceutical industry [1] Group 2 - Eli Lilly aims to further expand its business in immunology, building on its successes in diabetes and obesity treatments that have attracted investor and patient interest [1] - The company currently markets several drugs for inflammatory diseases, including Taltz, although the key patent protection for Taltz is set to expire in the coming years [1] - In 2024, Eli Lilly acquired Morphic Therapeutics for $3.2 billion to gain an experimental drug for inflammatory bowel disease and spent $2.4 billion on Dice Therapeutics, which develops oral therapies for psoriasis [2]